Close

Genomic Health (GHDX) Oncotype DX Met Primary Endpoint in Second DCIS Treatment Study

June 11, 2014 8:08 AM EDT Send to a Friend
Genomic Health (Nasdaq: GHDX) announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login